MedPath

The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose

Not Applicable
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000007714
Lead Sponsor
Department of Internal Medicine, School of Medicine, Keio University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1. type 1 diabetes mellitus 2. diabetes ketoacidosis, coma, or pre-coma 3. patients with severe infection, severe trauma, or in perioperative period 4. patients who have allergy to the medicine used in this trial 5.(possible) pregnant women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath